These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37783638)

  • 1. Recovery Mimicking "Ideal" CPAP Adherence Does Not Improve Wakefulness or Cognition in Chronic Murine Models of OSA: Effect of Wake-Promoting Agents.
    Badran M; Puech C; Barrow MB; Runion AR; Gozal D
    Arch Bronconeumol; 2023 Dec; 59(12):805-812. PubMed ID: 37783638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Solriamfetol enhances wakefulness and improves cognition and anxiety in a murine model of OSA.
    Badran M; Puech C; Barrow MB; Runion AR; Gozal D
    Sleep Med; 2023 Jul; 107():89-99. PubMed ID: 37137196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solriamfetol improves chronic sleep fragmentation-induced increases in sleep propensity and ameliorates explicit memory in male mice.
    Puech C; Badran M; Barrow MB; Runion AR; Gozal D
    Sleep; 2023 May; 46(5):. PubMed ID: 36866452
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Residual Daytime Sleepiness in Obstructive Sleep Apnea After Continuous Positive Airway Pressure Optimization: Causes and Management.
    Chapman JL; Serinel Y; Marshall NS; Grunstein RR
    Sleep Med Clin; 2016 Sep; 11(3):353-63. PubMed ID: 27542881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excessive Daytime Sleepiness in Obstructive Sleep Apnea. Mechanisms and Clinical Management.
    Lal C; Weaver TE; Bae CJ; Strohl KP
    Ann Am Thorac Soc; 2021 May; 18(5):757-768. PubMed ID: 33621163
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Wakefulness-Promoting Agents on Sleepiness in Patients with Sleep Apnea Treated with CPAP: A Meta-Analysis.
    Sukhal S; Khalid M; Tulaimat A
    J Clin Sleep Med; 2015 Oct; 11(10):1179-86. PubMed ID: 25979103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on Persistent Excessive Daytime Sleepiness in OSA.
    Javaheri S; Javaheri S
    Chest; 2020 Aug; 158(2):776-786. PubMed ID: 32147246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy and Safety of Wakefulness-Promoting Agents for Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea : A Systematic Review and Network Meta-analysis.
    Pitre T; Mah J; Roberts S; Desai K; Gu Y; Ryan C; Busse JW; Zeraatkar D
    Ann Intern Med; 2023 May; 176(5):676-684. PubMed ID: 37155992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modafinil improves daytime sleepiness in patients with mild to moderate obstructive sleep apnoea not using standard treatments: a randomised placebo-controlled crossover trial.
    Chapman JL; Kempler L; Chang CL; Williams SC; Sivam S; Wong KK; Yee BJ; Grunstein RR; Marshall NS
    Thorax; 2014 Mar; 69(3):274-9. PubMed ID: 24287166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Findings of the Maintenance of Wakefulness Test and its relationship with response to modafinil therapy for residual excessive daytime sleepiness in obstructive sleep apnea patients adequately treated with nasal continuous positive airway pressure.
    Inoue Y; Miki M; Tabata T
    Sleep Med; 2016; 27-28():45-48. PubMed ID: 27938918
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health-related impact of illness associated with excessive daytime sleepiness in patients with obstructive sleep apnea.
    Grandner MA; Min JS; Saad R; Leary EB; Eldemir L; Hyman D
    Postgrad Med; 2023 Jun; 135(5):501-510. PubMed ID: 37129416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of armodafinil on simulated driving and self-report measures in obstructive sleep apnea patients prior to treatment with continuous positive airway pressure.
    Kay GG; Feldman N
    J Clin Sleep Med; 2013 May; 9(5):445-54. PubMed ID: 23674935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of armodafinil on cortical activity and working memory in patients with residual excessive sleepiness associated with CPAP-Treated OSA: a multicenter fMRI study.
    Greve DN; Duntley SP; Larson-Prior L; Krystal AD; Diaz MT; Drummond SP; Thein SG; Kushida CA; Yang R; Thomas RJ
    J Clin Sleep Med; 2014 Feb; 10(2):143-53. PubMed ID: 24532997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol.
    Krief S; Berrebi-Bertrand I; Nagmar I; Giret M; Belliard S; Perrin D; Uguen M; Robert P; Lecomte JM; Schwartz JC; Finance O; Ligneau X
    Pharmacol Res Perspect; 2021 Oct; 9(5):e00855. PubMed ID: 34423920
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modafinil for treatment of residual excessive sleepiness in nasal continuous positive airway pressure-treated obstructive sleep apnea/hypopnea syndrome.
    Black JE; Hirshkowitz M
    Sleep; 2005 Apr; 28(4):464-71. PubMed ID: 16171291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of neurocognitive function and obstructive sleep apnea with or without daytime sleepiness.
    Zhou J; Camacho M; Tang X; Kushida CA
    Sleep Med; 2016 Jul; 23():99-108. PubMed ID: 27288049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Solriamfetol: A Review in Excessive Daytime Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnoea.
    Hoy SM
    CNS Drugs; 2023 Nov; 37(11):1009-1020. PubMed ID: 37847434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alertness and psychomotor performance effects of the histamine-3 inverse agonist MK-0249 in obstructive sleep apnea patients on continuous positive airway pressure therapy with excessive daytime sleepiness: a randomized adaptive crossover study.
    Herring WJ; Liu K; Hutzelmann J; Snavely D; Snyder E; Ceesay P; Lines C; Michelson D; Roth T
    Sleep Med; 2013 Oct; 14(10):955-63. PubMed ID: 23920422
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Controlled Trial of Solriamfetol for Excessive Daytime Sleepiness in OSA: An Analysis of Subgroups Adherent or Nonadherent to OSA Treatment.
    Schweitzer PK; Mayer G; Rosenberg R; Malhotra A; Zammit GK; Gotfried M; Chandler P; Baladi M; Strohl KP
    Chest; 2021 Jul; 160(1):307-318. PubMed ID: 33631141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating pharmacological treatments for excessive daytime sleepiness in obstructive sleep apnea: A comprehensive network meta-analysis and systematic review.
    Neshat SS; Heidari A; Henriquez-Beltran M; Patel K; Colaco B; Arunthari V; Lee Mateus AY; Cheung J; Labarca G
    Sleep Med Rev; 2024 Aug; 76():101934. PubMed ID: 38754208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.